scholarly journals Optimizing red blood cell transfusion therapy in the 21st century: the power of data analysis for past understanding and future guidance

Transfusion ◽  
2013 ◽  
Vol 53 (3) ◽  
pp. 470-475 ◽  
Author(s):  
Michelle Jean Taylor ◽  
Roslyn Yomtovian
Author(s):  
Shilpa Jain ◽  
Mark T. Gladwin

Sickle cell disease crises are precipitated by an acute occlusion of microvessels, which can lead to end organ ischaemia reperfusion injury and acute haemolysis. Acute fat emboli syndrome, acute lung injury (the acute chest syndrome), acute pulmonary hypertension, and cor pulmonale, haemorrhagic and occlusive stroke, and systemic infection represent the most common life-threatening complications observed in current ICU practice. General principles of management in all patients admitted to the critical care unit are hydration, antibiotics, pain control, and maintenance of oxygenation and ventilation. Red blood cell transfusion therapy is the treatment of choice for most complications of sickle cell disease requiring intensive care management. Transfusion of sickle negative, leukoreduced red blood cells, phenotypically matched for Rhesus and Kell antigens is the minimum standard of care in sickle cell disease patients as they have a high incidence of red blood cell alloimmunization.


Transfusion ◽  
2013 ◽  
Vol 53 (12) ◽  
pp. 3052-3059 ◽  
Author(s):  
Steven M. Frank ◽  
Linda M.S. Resar ◽  
James A. Rothschild ◽  
Elizabeth A. Dackiw ◽  
Will J. Savage ◽  
...  

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 4840-4840
Author(s):  
Mahogany Oldham ◽  
Gelina Sani ◽  
Stefanie Margulies ◽  
Jennifer Webb ◽  
Robert Sheppard Nickel ◽  
...  

Background: Sickle cell disease (SCD) is typically characterized as a red blood cell disorder but our understanding of the effects on the immune system is limited. Patients with sickle cell disease have been shown to have unique inflammatory profiles, immune phenotypes and function. Others have shown that during vaso-occlusive crises patients with SCD have elevated counts of neutrophils, monocytes, and cytokines as well as increased activity of invariant natural killer T cells (iNKT).We have previously shown that hydroxyurea use is associated with a normalization of the increased NK cell number and function. While there are studies that describe on the effects of single therapy, there is little known about combination therapy. Therefore, our study investigated immunological changes in pediatric patients on combination therapy, which was defined as hydroxyurea added to chronic red blood cell transfusion treatment. Methods: Patient data and peripheral blood samples were collected from an ongoing pilot study of combination therapy hydroxyurea and simple chronic transfusion in patients with SCD previously on chronic transfusion for stroke prevention. A total of 11 patients with hemoglobin SS were studied at two time points; baseline (on chronic RBC transfusion only) and 3 months follow up after initiation of hydroxyurea 20 mg/kg/day. Comparisons were performed using paired t-tests with a p-value <0.05 being considered significant. Results: T, B and NK cell percentage was similar between baseline and after 3 months of combination therapy 62.5% (44.3-71.9) vs 67% (17.6-82.7), 16.29%(8.15-30.2) vs. 13.26% (1.07-32.8) and 7.79% (4.16-14.7) vs. 6.88 (1.54-21) (p>0.05). There were no significant differences between markers of NK cell activation between baseline and 3 months as follows: NKG2D 4.89% (0.47-28.4) vs. 24.38% (0.88-63), and NKp30 8.40% (0.81-58.7) vs. 32.42% (0.45-86.9). However there was a significant decrease in the percentage of mature (CD57+) NK cells 33.8% (10.7-67.6) vs. 23.07%(4.23-37), p =0.005. Similar results were also seen when using absolute values of the different lymphocyte subsets. Conclusion: Combination therapy appears to not affect overall percentages of B, T and NK cells but does appear to decrease the percentage of mature CD57+ NK cells that are known to have increased cytolytic activity. We plan to investigate the implications of these findings using NK functional studies such as cytotoxicity assays and cytotoxic granule release to further elucidate if combination therapy can lead to a decrease in NK cell function to normal levels. Additionally we plan to assess the effect on the immune parameters at 1 year as the hydroxyurea effect is likely time-dependent. These findings may have implications for patients on chronic transfusion therapy who plan to undergo bone marrow transplantation where a reduction in the potential for graft rejection by NK cells is desired. Disclosures No relevant conflicts of interest to declare.


Transfusion ◽  
2018 ◽  
Vol 58 (11) ◽  
pp. 2513-2516 ◽  
Author(s):  
Ilyas Sahin ◽  
John L. Reagan ◽  
Rabin Niroula ◽  
Joseph D. Sweeney

2010 ◽  
Vol 27 (2) ◽  
pp. 112-121 ◽  
Author(s):  
Ellen Butensky James ◽  
Hendrik J. Vreman ◽  
Ronald J. Wong ◽  
David K. Stevenson ◽  
Elliott Vichinsky ◽  
...  

2018 ◽  
Vol 65 (12) ◽  
pp. e27423 ◽  
Author(s):  
Lee M. Hilliard ◽  
Varsha Kulkarni ◽  
Bisakha Sen ◽  
Cathy Caldwell ◽  
Christina Bemrich-Stolz ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document